Metabolic Characteristics of Plasma OxPLs in STEMI Patients.

NCT07382700 | Enrolling By Invitation

• 1 other identifier: 2025004A
• Study Type: observational
• Target: 240
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to investigate the structural composition and metabolic characteristics of OxPLs in STEMI patients. Explore OxPLs characteristic fingerprint biomarkers from different populations and analyze OxPLs fingerprint spectra. Based on the OxPLs fingerprint of STEMI patients, a machine learning classifier is used to establish an artificial intelligence assisted post PCI MACE risk prediction system, achieving the transformation of basic research into clinical application.

Conditions

STEMI - ST-segment Elevation Myocardial Infarction

Outcome Measures

Primary Outcomes (1)

• Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0

  12 months

Study Arms (4)

Healthy

Healthy people

CAD

Stable coronary heart disease patient

STEMI-M

Male patients with ST segment elevation myocardial infarction

STEMI-F

female patients with ST segment elevation myocardial infarction

Eligibility Criteria

• Age: 50 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

STEMI patients admitted to our cardiovascular department for concurrent PCI surgery between January 2025 and December 2025.

You may qualify if:

• The patient meets the diagnostic criteria for STEMI (refer to the "Diagnosis and Treatment Guidelines for Acute ST Segment Elevation Myocardial Infarction (2021)")
• Agree to perform direct PCI
• The onset time is less than 12 hours and successfully undergoing emergency PCI treatment
• After admission, all STEMI patients are routinely treated with antiplatelet aggregation, anticoagulation, lipid-lowering, and anti myocardial remodeling drugs.

You may not qualify if:

• Previous history of myocardial infarction
• Accompanied by other cardiovascular diseases, such as severe heart valve disease, severe heart failure, congenital heart disease, cardiomyopathy, etc
• Merge with severe infection
• Merge with severe anemia
• Merge with severe liver and kidney dysfunction
• Combined with malignant tumors
• Accompanied by a history of autoimmune or hematological diseases
• Recent history of severe trauma or surgery
• Patients with incomplete clinical data
• The patient does not agree to undergo data collection

Sponsors & Collaborators

• First Affiliated Hospital of Ningbo University: lead

Study Sites (1)

First Affiliated Hospital of Ningbo University

Ningbo, Zhejiang, 315010, China

Location

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 27, 2026
• First Posted: February 3, 2026
• Study Start: January 1, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2027
• Last Updated: February 3, 2026

Record last verified: 2026-01

Locations

CN (1)